US Bancorp
ACRS icon

US Bancorp’s Aclaris Therapeutics ACRS Stock Holding History

US Bancorp’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-754
Closed -$7.82K – 3979
2023
Q2 		$7.82K Buy
754
+227
+43% +$2.05K ﹤0.01% 3345
2023
Q1 		$4.26K Buy
527
+460
+687% +$5.84K ﹤0.01% 3572
2022
Q4 		$1.05K Hold
67
– – ﹤0.01% 3914
2022
Q3 		$1K Buy
+67
New +$1.06K ﹤0.01% 3904
2018
Q3 		– Sell
-68
Closed -$1K – 3617
2018
Q2 		$1K Buy
+68
New +$1.26K ﹤0.01% 3533

Other funds holding ACRS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

US Bancorp's ACRS Position: Q3 2023 in Review

US Bancorp sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 754 shares — an estimated $7.82K sold.

US Bancorp first reported a position in ACRS in Q2 2018 and held it in 5 quarters. The position peaked at $7.82K in Q2 2023. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

  • US Bancorp reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
  • US Bancorp sold 754 Aclaris Therapeutics shares in Q3 2023, an estimated $7.82K.
  • US Bancorp first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 5 quarters.
  • US Bancorp's Aclaris Therapeutics position peaked at $7.82K in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on US Bancorp's 13F filing for Q3 2023, filed 3 Nov 2023.